New drug aims to tame autoimmune hepatitis and cut steroid use
NCT ID NCT07598825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive either inebilizumab or a placebo by IV, along with standard care, and be followed for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inebilizumab (a drug given by IV infusion that targets immune cells)
What this could lead to
If it works, this could offer a new treatment option for people with autoimmune hepatitis, helping control the disease with less reliance on steroids.
What could go wrong
This is an early-stage trial (Phase 2/3) with only 180 participants. The drug may not prove effective or could have side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••